Cargando…
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
Neutropenia is a dose‐related treatment‐limiting and costly adverse event of pemetrexed. We postulate that individualized dosing reduces the incidence of neutropenia. The aims of this study were (i) to investigate the costs of pemetrexed‐related neutropenia and (ii) to determine the pharmacoeconomic...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304220/ https://www.ncbi.nlm.nih.gov/pubmed/35048355 http://dx.doi.org/10.1002/cpt.2529 |